SCHEMBL21150809

SCHEMBL21150809

C#Cc1ccc(OCC(=O)N2CCC(N3CC(=O)N(c4ccccc4)C3=O)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.48
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
TP53 P04637 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
GAA P10253 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21150807 0.88 ACHE (0.53) ACHEKDM4EALDH1A1MAPTTDP1
SCHEMBL21152121 0.88 ALDH1A1 (0.52) ACHEKDM4EALDH1A1MAPTTDP1
SCHEMBL21151289 0.86 ACHE (0.44) ACHEKDM4EALDH1A1MAPTTDP1
SCHEMBL21150808 0.86 KDM4E (0.46) ACHEKDM4EALDH1A1MAPTTDP1
SCHEMBL21150805 0.78 YAP1 (0.46) KDM4EALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL21150798 0.71 GPR119 (0.57) KDM4EMAPTTP53POLB
SCHEMBL29590229 0.67 GRM4 (0.48) ALDH1A1MAPTTDP1TP53SMN1; SMN2
SCHEMBL21150757 0.66 ALDH1A1 (0.39) KDM4EALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL10721826 0.65 MEN1 (1.00) KDM4EALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL14578661 0.65 ALDH1A1 (0.78) ACHEKDM4EALDH1A1TDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B ACHE 1903/4885KDM4E 2126/4885ALDH1A1 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.